Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
Go back to Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration| Beam Inc. (NASDAQ: BEAM) | Delayed: 25.27 +0.32 (1.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.95 | 52 Week High | $83.60 | |||
| Open | $25.45 | 52 Week Low | $82.96 | |||
| Day High | $25.66 | P/E | 11.28 | |||
| Day Low | $24.83 | EPS | $2.24 | |||
| Volume | 694,846 | |||||
| Beam Inc. (NASDAQ: BEAM) | Delayed: 25.27 +0.32 (1.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.95 | 52 Week High | $83.60 | |||
| Open | $25.45 | 52 Week Low | $82.96 | |||
| Day High | $25.66 | P/E | 11.28 | |||
| Day Low | $24.83 | EPS | $2.24 | |||
| Volume | 694,846 | |||||
